A secondary analysis of the AUGUSTUS trial confirms earlier findings that treating heart patients with the anticoagulant apixaban results in less major bleeding, hospitalization and death than warfarin, a standard-of-care blood thinner.

The editors of the Journal of the American Heart Association have retracted a study that linked some-day and everyday e-cigarette use to an increased risk of having had a heart attack. The same study alleged the effect of e-cigarettes was comparable to those of conventional cigarettes.

Women who have suffered domestic abuse are 31% more likely to develop heart disease and 51% more likely to develop type 2 diabetes than women who haven’t been abused, a study out of the U.K. has found.

Research out of the Yale School of Public Health in New Haven, Conn., has revealed a relationship between rosiglitazone, a type 2 diabetes drug, and heart disease.

A recent review of pivotal cancer drug trials suggests that CVD and adverse cardiovascular outcomes are underreported in studies of new cancer therapies, despite an increasing risk of cardiotoxicity in oncological drugs.

A beta-blocker and aspirin combination may help attenuate the heightened CVD risk observed in people who have recently lost a loved one, according to research published in the American Heart Journal in February.

Over half of heart patients on a triple-drug regimen of ACE inhibitors, statins and either calcium channel blockers or aspirin are nonadherent to their medications, researchers reported in the American Journal of Cardiology Feb. 6.

A 90-second chest scan could be a game-changer for triaging patients who present to the emergency department with undiagnosed chest pain, according to research out of Detroit.

A simple ECG score could help physicians estimate infarct size in patients with prior MI, according to work published Jan. 24 in the Journal of the American Heart Association.

A study published in the latest edition of JACC: Cardiovascular Imaging suggests cardiac magnetic resonance imaging can be as effective as measurements of fractional flow reserve in evaluating nonculprit lesions after STEMI.

Amarin on Jan. 13 announced the launch of True to Your Heart, a new educational campaign geared toward heart patients who remain at a persistent risk for CVD despite being treated with statins and other standard-of-care therapies.

An analysis of 12 recent randomized clinical trials suggests a majority of patients with ischemic heart disease or a history of MI are eligible for new secondary prevention therapies—a finding that, if acted upon, could change a paradigm that’s been in place for decades.